Soleno Therapeutics (SLNO)

Slide schematic 4/4

paragraph 2/2 source-note 1/1 title 1/1

Components 4

paragraph paragraph source-note headline

Tools 1

Trial investigator #1 expressed extreme concern about safety signals emerging with Vykat, similar to the fatalities that led to the termination of the Zafgen drug.

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

antagonist-introduction 80%

The slide frames the drug/company as a safety risk by introducing a critical expert voice.

Find anything

The slide uses direct quotes from a KOL to build a case against the safety profile of the drug.